{
    "2018-12-20": [
        [
            {
                "time": "2018-12-20",
                "original_text": "Tilray CEO still thinks his cannabis company could be worth $100 billion even with the extreme stock market volatility",
                "features": {
                    "keywords": [
                        "Tilray",
                        "CEO",
                        "cannabis",
                        "worth",
                        "stock market volatility"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "cannabis"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "GSK, Pfizer and GE shift away from diversification in latest round of health-care deals",
                "features": {
                    "keywords": [
                        "GSK",
                        "Pfizer",
                        "GE",
                        "diversification",
                        "health-care deals"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "Is Tilray Stock a Must-Buy Following New Partnership?",
                "features": {
                    "keywords": [
                        "Tilray",
                        "Stock",
                        "Must-Buy",
                        "Partnership"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "Novartis oncology boss Barrett makes quick exit",
                "features": {
                    "keywords": [
                        "Novartis",
                        "oncology",
                        "boss",
                        "Barrett",
                        "exit"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "Pre-Market Most Active for Dec 20, 2018: NVS, SQQQ, DBVT, AMD, GE, QQQ, SBGL, BHP, MU, TQQQ, GSK, LYG",
                "features": {
                    "keywords": [
                        "Pre-Market",
                        "Most Active",
                        "NVS",
                        "SQQQ",
                        "DBVT",
                        "AMD",
                        "GE",
                        "QQQ",
                        "SBGL",
                        "BHP",
                        "MU",
                        "TQQQ",
                        "GSK",
                        "LYG"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "healthcare",
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",
                "features": {
                    "keywords": [
                        "Tilray",
                        "Cannabis",
                        "Drink Pact",
                        "Merck",
                        "FDA",
                        "Spectrum"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "cannabis"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "Novartis appoints Susanne Schaffert to lead oncology business",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Susanne Schaffert",
                        "oncology",
                        "appoints"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "Major pharma companies plan to raise drug prices in January: report",
                "features": {
                    "keywords": [
                        "pharma",
                        "companies",
                        "drug prices",
                        "January"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "Exclusive: Big Pharma returning to U.S. price hikes in January after pause",
                "features": {
                    "keywords": [
                        "Big Pharma",
                        "U.S.",
                        "price hikes",
                        "January",
                        "pause"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-12-20",
                "original_text": "7 Stocks That Made Big Moves After-hours (TLRY, SPPI, ADMA, DBVT...)",
                "features": {
                    "keywords": [
                        "Stocks",
                        "Big Moves",
                        "After-hours",
                        "TLRY",
                        "SPPI",
                        "ADMA",
                        "DBVT"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "various"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}